Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Perfuze's NeuroSheath, an 8F long sheath for neurovascular access during stroke thrombectomy, has received FDA 510(k) clearance. The device accommodates larger-bore aspiration catheters — up to 0.088 inches — overcoming limitations of the commonly used 6F sheaths. A limited US market release at select stroke centers is underway, with a full launch expected in 2027.
Perfuze completes its stroke thrombectomy lineup with FDA-cleared NeuroSheath
Perfuze, a neurovascular device company based in Galway, Ireland, has secured FDA 510(k) clearance for NeuroSheath — an 8 French (8F) long sheath designed to provide vascular access during mechanical thrombectomy for acute ischemic stroke. The clearance rounds out Perfuze's integrated stroke system, which also includes its Millipede88 and Millipede70 aspiration catheters and Zipline access catheters.
The key innovation here is compatibility: larger-bore aspiration catheters (up to 0.088-inch inner diameter) have historically required 8F sheaths, but navigating those through challenging vascular anatomy has been a persistent hurdle. NeuroSheath is engineered to handle that while maintaining maneuverability — even in complex anatomies like a Type III aortic arch. As one physician put it, the goal is for "the case to decide the catheter, not the sheath."
Key Takeaways
Why it matters: Stroke thrombectomy outcomes are heavily dependent on access — getting the right catheter to the clot quickly. By offering a complete, purpose-built system from groin access to clot aspiration, Perfuze is positioning itself to streamline procedures and potentially improve reperfusion rates for stroke patients.